Steering innovation in cancer therapeutics

AUM’s value driven drug development process for innovative cancer therapeutics, is a culmination of several decades of research in the treatment of Asia-prevalent cancers. With a singular goal of making cancer treatment accessible and affordable to all, AUM is led by a team of clinicians and medical researchers with global & diverse, clinical and commercial experience of 100+ years. Every stakeholder is passionate about what they do, with an emphasis on democratising cancer management and treatment.

vishal-doshi
VISHAL DOSHI, Chairman, Chief Executive Officer
  • Extensive experience in structuring and managing risk sharing deals in various roles worth over $1 billion USD.
  • Extensive experience in clinical research across the pharmaceutical and CRO industry, spanning US, Europe and Asia
  • Key Opinion Leader to Korean Health Industry Development Institute
  • Previously held senior business development and management roles at IQVIA, EPS International and ICON
  • Master’s Degree in Pharmaceutical Sciences from Kingston University with research focus in Aromatase inhibitors in Breast cancer
  • Bachelor of Pharmacy from University of Mumbai
zou-bin
Dr. HARISH DAVE, Co-Founder, Chief Medical Officer
  • Board-certified oncologist and hematologist with more than 35 years of experience
  • Conducted over 100 studies in hematology, oncology and transplantation
  • Extensive experience in managing regulatory authorities including successful submission of over 50 INDs
  • Structured and executed a private equity Novaquest–sponsored strategic virtual drug development collaboration between Quintiles and Eisai
  • Held various senior management positions at IQVIA, George Washington University Medical Center and VA Medical Center in Washington
harish-dave
TERIG HUGHES, Chief Financial Officer
  • Over 25 years of international experience in healthcare, scientific and medical publishing, information and analytics
  • Extensive financial management experience in growing businesses, with portfolios up to $400 million in annual turnover
  • M&A experience spanning Europe, USA and Asia and deals ranging from a $2 million JV formation with a leading Chinese University to integration of a $4.5 billion acquisition in the US
  • Previous senior leadership roles in Asia with Elsevier, as Finance Director for the Health Sciences Division, and Managing Director for India and South East Asia
john-patava
Dr. JOHN PATAVA, Chief Operating Officer
  • 25 years of experience in medical research and clinical development of therapeutics products, including a 10-year period leading clinical operations at Bayer
  • Global Head of Scientific Affairs at Sirtex Technology Pty Ltd, an Australian listed oncology company, where he managed a global clinical operations budget in excess of A$20 million
  • Successfully delivered Sirtex’s global pivotal studies with a combined enrolment of 1103 patients, in over 200 investigator sites in 24 countries
  • Global Head of Biosimilar Development Business Group within Quintiles
  • Managed clinical trials in the indications of oncology, renal medicine, Chron’s disease, multiple sclerosis, hematology and surgery.
james.jpg
Dr.James Cornwall,Chief Business officer
  • Over 25 years of experience in operations, sales, deal execution and alliance development in Pharma, biotech and CRO
  • Part of a small team responsible for the commitment of over $2.7bn investment in the Pharma space over 10 years Quintiles/PharmaBio Development
  • Lived and worked in Europe, USA and Asia
  • Instrumental in the $30m joint venture transaction between Quintiles and Samsung and served on the Board of Directors at Samsung Biologics, the entity created in the transaction, for 3 years.
  • Created and led governance structure, operational delivery model for clinical and consulting relationships with key Korean customers at Quintiles
  • Served on the Asia Markets Leadership Team and Asia Pacific Regional Board for Quintiles
  • Led ‘EBio’ biotech investment model in EU and US while at Quintiles where he managed 8 biotech equity investments/relationships
  • Previously, VP of Corporate Development, Quintiles Asia Pacific, Boston MA, and UK
  • BSc in Pharmacology, PhD in Neuropharmacology from the University Of Bristol
  • Completed postgraduate training in Executive Leadership, University of North Carolina Kenan Flagler Business School.
  • Held research positions in Glaxo Group Research UK and University of Bristol